弱毒生ワクチンの世界市場レポート2025年

弱毒生ワクチン市場規模は、今後数年間で力強い成長が見込まれます。2029年の年間平均成長率（CAGR）は9.7%で、375億6,000万米ドルに成長します。予測期間中の成長は、予防ヘルスケアの重視の高まり、中低所得国でのワクチン導入の拡大、アウトブレイク対策への支援の強化、旅行関連の予防接種需要の高まり、政府資金による予防接種イニシアチブの拡大などに起因すると考えられます。この期間に予想される主な動向としては、ワクチン送達技術の発展、遺伝子減弱法の革新、研究開発投資の増加、耐熱性ワクチン製剤の開発、予防接種プログラムへのデジタル技術の統合などが挙げられます。

感染症の流行増加は、弱毒生ワクチン市場の大幅な成長を促進すると予想されます。細菌、ウイルス、真菌、寄生虫が原因となる感染症は、特に世界の旅行者の増加により、国境を越えた病原体の伝播が促進され、急速に広がる可能性があります。弱毒生ワクチンは、病原体の弱体化した形を使って強力かつ長期的な免疫反応を誘導することにより、効果的な防御を提供し、感染症の発生を抑制することで、これらの病気と闘う上で重要な役割を果たしています。例えば、2025年3月、世界保健機関（WHO）は、2023年には世界で約1,080万人が結核に罹患し、その内訳は男性600万人、女性360万人、子供130万人であると報告しました。このような感染症負担の増大は、世界の疾病予防における弱毒生ワクチンの重要な役割を浮き彫りにし、市場拡大に拍車をかけています。

弱毒生ワクチン市場の主要企業は、予防接種の成果や患者のアドヒアランスを向上させるため、単回投与ワクチンのような革新的ソリューションの開発にますます力を注いでいます。単回投与ワクチンは、たった1回の注射で持続的な免疫を提供するため、ワクチン接種プロトコルが合理化され、ヘルスケア・システムの物流上の課題が軽減されます。このアプローチにより、フォローアップ接種の必要性がなくなるため、患者のコンプライアンスが向上します。例えば、感染症ワクチンを専門とするフランスのバイオテクノロジー企業であるバルネバSEは、2023年11月、世界初のチクングニア用弱毒化生ワクチンIXCHIQを発売しました。同ワクチンは米国食品医薬品局（FDA）より18歳以上の成人への使用が承認されました。IXCHIQは、蚊が媒介するウイルス感染症で、高熱、関節痛、筋肉痛、その他の衰弱症状を引き起こすことで知られるチクングニアに対する予防を提供することで、重要なアンメット・ニーズに対応します。今回の承認は、弱毒生ワクチンの分野における重要な進歩であり、簡便な単回投与による予防接種戦略への業界のシフトを浮き彫りにするものです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、貿易戦争と関税、そしてコロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の弱毒生ワクチン：PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の弱毒生ワクチン市場：成長率分析
• 世界の弱毒生ワクチン市場の実績：規模と成長, 2019-2024
• 世界の弱毒生ワクチン市場の予測：規模と成長, 2024-2029, 2034F
• 世界の弱毒生ワクチン：総潜在市場規模（TAM）

第6章 市場セグメンテーション

• 世界の弱毒生ワクチン市場ワクチンの種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 一価
• 多価
• 世界の弱毒生ワクチン市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 筋肉内
• 皮下
• 経口弱毒化
• 鼻腔内弱毒化
• 世界の弱毒生ワクチン市場：適応症別、実績と予測, 2019-2024, 2024-2029F, 2034F
• インフルエンザ
• 麻疹・風疹・おたふく風邪（MMR）
• ポリオ
• 水疱瘡
• 帯状疱疹
• ロタウイルス
• その他の適応症
• 世界の弱毒生ワクチン市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局
• オンライン薬局
• 世界の弱毒生ワクチン市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• クリニック
• 診断センター
• 調査機関
• その他のエンドユーザー
• 世界の弱毒生ワクチン市場、一価のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 単回接種ワクチン
• 複数回接種ワクチン
• 世界の弱毒生ワクチン市場、多価のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 二価ワクチン
• 三価ワクチン
• 四価ワクチン
• その他の多価ワクチン

第7章 地域別・国別分析

• 世界の弱毒生ワクチン市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の弱毒生ワクチン市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 弱毒生ワクチン市場：競合情勢
• 弱毒生ワクチン市場：企業プロファイル
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi SA Overview, Products and Services, Strategy and Financial Analysis
  • AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
  • Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
  • GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Takeda Pharmaceutical Company Limited
• Boehringer Ingelheim International GmbH
• CSL Limited
• GC Biopharma
• Serum Institute of India Pvt. Ltd.
• Bavarian Nordic
• Valneva SE
• Southern Research
• BioFarma
• Bharat Biotech International Limited
• Meissa Vaccines Inc.
• BioDiem Ltd.
• Bio-Med Limited
• Lakshmi Pharmaceuticals
• Biosynth AG

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 弱毒生ワクチン市場2029：新たな機会を提供する国
• 弱毒生ワクチン市場2029：新たな機会を提供するセグメント
• 弱毒生ワクチン市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Live attenuated vaccines are biological preparations that contain a weakened form of a virus or bacterium, designed in a laboratory to ensure it does not cause illness in healthy individuals. These vaccines closely mimic a natural infection, thereby stimulating a strong and long-lasting immune response, often requiring just one or two doses to provide effective protection against infectious diseases.

The primary categories of live attenuated vaccines include monovalent and multivalent types. Monovalent vaccines are formulated to target a single specific antigen, strain, or type. These vaccines are administered through various routes, including intramuscular, subcutaneous, oral attenuated, and intranasal attenuated methods. They are used to prevent diseases such as influenza, measles, mumps, rubella (MMR), polio, chickenpox, shingles, rotavirus, and others. Distribution occurs through hospital pharmacies, retail pharmacies, and online pharmacies, with end-users including hospitals, clinics, diagnostic centers, research institutes, and more.

The live attenuated vaccines market research report is one of a series of new reports from The Business Research Company that provides live attenuated vaccines market statistics, including the live attenuated vaccines industry global market size, regional shares, competitors with the live attenuated vaccines market share, detailed live attenuated vaccines market segments, market trends, and opportunities, and any further data you may need to thrive in the live attenuated vaccines industry. These live attenuated vaccines market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The live attenuated vaccines market size has grown rapidly in recent years. It will grow from $23.58 billion in 2024 to $25.95 billion in 2025 at a compound annual growth rate (CAGR) of 10.1%. The growth during the historic period can be attributed to the expansion of global immunization coverage, increased public health expenditure, heightened awareness about disease prevention, rising demand for pediatric vaccines, and the broadening of vaccination initiatives and programs.

The live attenuated vaccines market size is expected to see strong growth in the next few years. It will grow to $37.56 billion in 2029 at a compound annual growth rate (CAGR) of 9.7%. The projected growth in the forecast period can be attributed to an increased emphasis on preventive healthcare, broader adoption of vaccines in low- and middle-income countries, enhanced support for outbreak preparedness, rising demand for travel-related vaccinations, and the expansion of government-funded immunization initiatives. Key trends expected during this period include advancements in vaccine delivery technologies, innovations in genetic attenuation methods, increased investment in research and development, the creation of thermostable vaccine formulations, and the integration of digital technologies into immunization programs.

The rising prevalence of infectious diseases is expected to drive significant growth in the live attenuated vaccines market. Infectious diseases-caused by bacteria, viruses, fungi, or parasites-can spread rapidly, particularly due to increased global travel, which facilitates faster transmission of pathogens across borders. Live attenuated vaccines play a critical role in combating these diseases by inducing strong, long-lasting immune responses using weakened forms of the pathogens, thereby offering effective protection and helping curb outbreaks. For example, in March 2025, the World Health Organization reported that in 2023, approximately 10.8 million people contracted tuberculosis (TB) globally, including 6.0 million men, 3.6 million women, and 1.3 million children. This growing burden of infectious diseases underscores the essential role of live attenuated vaccines in global disease prevention, fueling market expansion.

Major companies in the live attenuated vaccines market are increasingly focusing on developing innovative solutions such as single-dose vaccines to improve immunization outcomes and patient adherence. Single-dose vaccines offer durable immunity with just one injection, streamlining vaccination protocols and reducing logistical challenges for healthcare systems. This approach improves patient compliance by eliminating the need for follow-up doses. For example, in November 2023, Valneva SE, a France-based biotechnology company specializing in vaccines for infectious diseases, launched IXCHIQ, the world's first live-attenuated vaccine for chikungunya. The vaccine received approval from the U.S. Food and Drug Administration (FDA) for use in adults aged 18 and older. IXCHIQ addresses a critical unmet need by offering protection against chikungunya-a mosquito-borne viral infection known for causing high fever, joint and muscle pain, and other debilitating symptoms. This approval marks a significant advancement in the field of live attenuated vaccines and highlights the industry's shift toward convenient, single-dose immunization strategies.

In May 2023, Bavarian Nordic A/S, a Denmark-based biotechnology company, acquired the travel health business of Emergent BioSolutions Inc. for approximately $380 million. This strategic acquisition aims to broaden Bavarian Nordic's vaccine portfolio by including key products such as VIVOTIF (for typhoid fever), VAXCHORA (for cholera), and the CHIKV VLP chikungunya vaccine candidate. The deal also includes the acquisition of manufacturing and development facilities located in Switzerland and California, enhancing the company's production capabilities and global footprint. Emergent BioSolutions Inc., a US-based biopharmaceutical company, is known for manufacturing live attenuated vaccines and other infectious disease solutions.

Major players in the live attenuated vaccines market are Merck & Co. Inc., Sanofi SA, AstraZeneca plc, Abbott Laboratories, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, CSL Limited, GC Biopharma, Serum Institute of India Pvt. Ltd., Bavarian Nordic, Valneva SE, Southern Research, BioFarma, Bharat Biotech International Limited, Meissa Vaccines Inc., BioDiem Ltd., Bio-Med Limited, Naobios, Lakshmi Pharmaceuticals

North America was the largest region in the live attenuated vaccines market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in live attenuated vaccine report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the live attenuated vaccine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The live attenuated vaccine market consists of sales of viral live attenuated vaccines, bacterial live attenuated vaccines, and intranasal live attenuated vaccines. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Live Attenuated Vaccines Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on live attenuated vaccines market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for live attenuated vaccines ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The live attenuated vaccines market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Vaccine Type: Monovalent; Multivalent
• 2) By Route Of Administration: Intramuscular; Subcutaneous; Oral Attenuated; Intranasal Attenuated
• 3) By Indication: Influenza; Measles, Mumps and Rubella (MMR); Polio; Chickenpox; Shingles; Rotavirus; Other Indications
• 4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• 5) By End-User: Hospitals; Clinics; Diagnostic Centers; Research Institute; Other End-Users
• Subsegments:
• 1) By Monovalent: Single-Dose Vaccines; Multiple-Dose Vaccines
• 2) By Multivalent: Bivalent Vaccines; Trivalent Vaccines; Quadrivalent Vaccines; Other Multivalent Vaccines
• Companies Mentioned: Merck & Co. Inc.; Sanofi SA; AstraZeneca plc; Abbott Laboratories; GlaxoSmithKline plc
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Live Attenuated Vaccines Market Characteristics

3. Live Attenuated Vaccines Market Trends And Strategies

4. Live Attenuated Vaccines Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Live Attenuated Vaccines Growth Analysis And Strategic Analysis Framework

• 5.1. Global Live Attenuated Vaccines PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Live Attenuated Vaccines Market Growth Rate Analysis
• 5.4. Global Live Attenuated Vaccines Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Live Attenuated Vaccines Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Live Attenuated Vaccines Total Addressable Market (TAM)

6. Live Attenuated Vaccines Market Segmentation

• 6.1. Global Live Attenuated Vaccines Market, Segmentation By Vaccines Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Monovalent
• Multivalent
• 6.2. Global Live Attenuated Vaccines Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Intramuscular
• Subcutaneous
• Oral Attenuated
• Intranasal Attenuated
• 6.3. Global Live Attenuated Vaccines Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Influenza
• Measles, Mumps And Rubella (MMR)
• Polio
• Chickenpox
• Shingles
• Rotavirus
• Other Indications
• 6.4. Global Live Attenuated Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• 6.5. Global Live Attenuated Vaccines Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Clinics
• Diagnostic Centers
• Research Institute
• Other End-Users
• 6.6. Global Live Attenuated Vaccines Market, Sub-Segmentation Of Monovalent, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Single-Dose Vaccines
• Multiple-Dose Vaccines
• 6.7. Global Live Attenuated Vaccines Market, Sub-Segmentation Of Multivalent, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Bivalent Vaccines
• Trivalent Vaccines
• Quadrivalent Vaccines
• Other Multivalent Vaccines

7. Live Attenuated Vaccines Market Regional And Country Analysis

• 7.1. Global Live Attenuated Vaccines Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Live Attenuated Vaccines Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Live Attenuated Vaccines Market

• 8.1. Asia-Pacific Live Attenuated Vaccines Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Live Attenuated Vaccines Market, Segmentation By Vaccines Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Live Attenuated Vaccines Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Live Attenuated Vaccines Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Live Attenuated Vaccines Market

• 9.1. China Live Attenuated Vaccines Market Overview
• 9.2. China Live Attenuated Vaccines Market, Segmentation By Vaccines Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Live Attenuated Vaccines Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Live Attenuated Vaccines Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Live Attenuated Vaccines Market

• 10.1. India Live Attenuated Vaccines Market, Segmentation By Vaccines Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Live Attenuated Vaccines Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Live Attenuated Vaccines Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Live Attenuated Vaccines Market

• 11.1. Japan Live Attenuated Vaccines Market Overview
• 11.2. Japan Live Attenuated Vaccines Market, Segmentation By Vaccines Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Live Attenuated Vaccines Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Live Attenuated Vaccines Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Live Attenuated Vaccines Market

• 12.1. Australia Live Attenuated Vaccines Market, Segmentation By Vaccines Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Live Attenuated Vaccines Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Live Attenuated Vaccines Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Live Attenuated Vaccines Market

• 13.1. Indonesia Live Attenuated Vaccines Market, Segmentation By Vaccines Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Live Attenuated Vaccines Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Live Attenuated Vaccines Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Live Attenuated Vaccines Market

• 14.1. South Korea Live Attenuated Vaccines Market Overview
• 14.2. South Korea Live Attenuated Vaccines Market, Segmentation By Vaccines Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Live Attenuated Vaccines Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Live Attenuated Vaccines Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Live Attenuated Vaccines Market

• 15.1. Western Europe Live Attenuated Vaccines Market Overview
• 15.2. Western Europe Live Attenuated Vaccines Market, Segmentation By Vaccines Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Live Attenuated Vaccines Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Live Attenuated Vaccines Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Live Attenuated Vaccines Market

• 16.1. UK Live Attenuated Vaccines Market, Segmentation By Vaccines Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Live Attenuated Vaccines Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Live Attenuated Vaccines Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Live Attenuated Vaccines Market

• 17.1. Germany Live Attenuated Vaccines Market, Segmentation By Vaccines Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Live Attenuated Vaccines Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Live Attenuated Vaccines Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Live Attenuated Vaccines Market

• 18.1. France Live Attenuated Vaccines Market, Segmentation By Vaccines Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Live Attenuated Vaccines Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Live Attenuated Vaccines Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Live Attenuated Vaccines Market

• 19.1. Italy Live Attenuated Vaccines Market, Segmentation By Vaccines Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Live Attenuated Vaccines Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Live Attenuated Vaccines Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Live Attenuated Vaccines Market

• 20.1. Spain Live Attenuated Vaccines Market, Segmentation By Vaccines Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Live Attenuated Vaccines Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Live Attenuated Vaccines Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Live Attenuated Vaccines Market

• 21.1. Eastern Europe Live Attenuated Vaccines Market Overview
• 21.2. Eastern Europe Live Attenuated Vaccines Market, Segmentation By Vaccines Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Live Attenuated Vaccines Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Live Attenuated Vaccines Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Live Attenuated Vaccines Market

• 22.1. Russia Live Attenuated Vaccines Market, Segmentation By Vaccines Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Live Attenuated Vaccines Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Live Attenuated Vaccines Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Live Attenuated Vaccines Market

• 23.1. North America Live Attenuated Vaccines Market Overview
• 23.2. North America Live Attenuated Vaccines Market, Segmentation By Vaccines Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Live Attenuated Vaccines Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Live Attenuated Vaccines Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Live Attenuated Vaccines Market

• 24.1. USA Live Attenuated Vaccines Market Overview
• 24.2. USA Live Attenuated Vaccines Market, Segmentation By Vaccines Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Live Attenuated Vaccines Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Live Attenuated Vaccines Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Live Attenuated Vaccines Market

• 25.1. Canada Live Attenuated Vaccines Market Overview
• 25.2. Canada Live Attenuated Vaccines Market, Segmentation By Vaccines Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Live Attenuated Vaccines Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Live Attenuated Vaccines Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Live Attenuated Vaccines Market

• 26.1. South America Live Attenuated Vaccines Market Overview
• 26.2. South America Live Attenuated Vaccines Market, Segmentation By Vaccines Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Live Attenuated Vaccines Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Live Attenuated Vaccines Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Live Attenuated Vaccines Market

• 27.1. Brazil Live Attenuated Vaccines Market, Segmentation By Vaccines Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Live Attenuated Vaccines Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Live Attenuated Vaccines Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Live Attenuated Vaccines Market

• 28.1. Middle East Live Attenuated Vaccines Market Overview
• 28.2. Middle East Live Attenuated Vaccines Market, Segmentation By Vaccines Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Live Attenuated Vaccines Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Live Attenuated Vaccines Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Live Attenuated Vaccines Market

• 29.1. Africa Live Attenuated Vaccines Market Overview
• 29.2. Africa Live Attenuated Vaccines Market, Segmentation By Vaccines Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Live Attenuated Vaccines Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Live Attenuated Vaccines Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Live Attenuated Vaccines Market Competitive Landscape And Company Profiles

• 30.1. Live Attenuated Vaccines Market Competitive Landscape
• 30.2. Live Attenuated Vaccines Market Company Profiles
  • 30.2.1. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Sanofi SA Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis

31. Live Attenuated Vaccines Market Other Major And Innovative Companies

• 31.1. Takeda Pharmaceutical Company Limited
• 31.2. Boehringer Ingelheim International GmbH
• 31.3. CSL Limited
• 31.4. GC Biopharma
• 31.5. Serum Institute of India Pvt. Ltd.
• 31.6. Bavarian Nordic
• 31.7. Valneva SE
• 31.8. Southern Research
• 31.9. BioFarma
• 31.10. Bharat Biotech International Limited
• 31.11. Meissa Vaccines Inc.
• 31.12. BioDiem Ltd.
• 31.13. Bio-Med Limited
• 31.14. Lakshmi Pharmaceuticals
• 31.15. Biosynth AG

32. Global Live Attenuated Vaccines Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Live Attenuated Vaccines Market

34. Recent Developments In The Live Attenuated Vaccines Market

35. Live Attenuated Vaccines Market High Potential Countries, Segments and Strategies

• 35.1 Live Attenuated Vaccines Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Live Attenuated Vaccines Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Live Attenuated Vaccines Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer